Evidence map›Paper›PMID 36975539›Full record

ArticleCurrent issues in molecular biology2023

Alteration of Mesenchymal Stem Cells Isolated from Glioblastoma Multiforme under the Influence of Photodynamic Treatment.

Kalina Tumangelova-Yuzeir, Krassimir Minkin, Ivan Angelov, Ekaterina Ivanova-Todorova, Ekaterina Kurteva, Georgi Vasilev, Jeliazko Arabadjiev, Petar Karazapryanov, Kaloyan Gabrovski, Lidia Zaharieva and 2 more

Open access · goldFull text read
In one paragraph

Article in Current issues in molecular biology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.3field-weighted citation impact, top 49% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 3 institutions in 1 country.

Kalina Tumangelova-YuzeirLaboratory of Clinical Immunology, University Hospital "St. Ivan Rilski", Medical University of Sofia, 1431 Sofia, Bulgaria.ORCID 0000-0001-6143-7538
Krassimir MinkinClinic of Neurosurgery, University Hospital "St. Ivan Rilski", Medical University of Sofia, 1431 Sofia, Bulgaria.
Ivan AngelovInstitute of Organic Chemistry with Centre of Phytochemistry, Bulgarian Academy of Sciences, 1113 Sofia, Bulgaria.
Ekaterina Ivanova-TodorovaLaboratory of Clinical Immunology, University Hospital "St. Ivan Rilski", Medical University of Sofia, 1431 Sofia, Bulgaria.
Ekaterina KurtevaLaboratory of Clinical Immunology, University Hospital "St. Ivan Rilski", Medical University of Sofia, 1431 Sofia, Bulgaria.ORCID 0000-0003-1968-5962
Georgi VasilevLaboratory of Clinical Immunology, University Hospital "St. Ivan Rilski", Medical University of Sofia, 1431 Sofia, Bulgaria.ORCID 0000-0002-6314-6889
Jeliazko ArabadjievAcibadem City Clinic, University Hospital "Tokuda", 1407 Sofia, Bulgaria.ORCID 0000-0003-2440-2760
Petar KarazapryanovClinic of Neurosurgery, University Hospital "St. Ivan Rilski", Medical University of Sofia, 1431 Sofia, Bulgaria.ORCID 0000-0001-5855-731X
Kaloyan GabrovskiClinic of Neurosurgery, University Hospital "St. Ivan Rilski", Medical University of Sofia, 1431 Sofia, Bulgaria.
Lidia ZaharievaInstitute of Electronics, Bulgarian Academy of Sciences, 1784 Sofia, Bulgaria.ORCID 0000-0003-1898-4477
Tsanislava GenovaInstitute of Electronics, Bulgarian Academy of Sciences, 1784 Sofia, Bulgaria.ORCID 0000-0002-7792-8259
Dobroslav KyurkchievLaboratory of Clinical Immunology, University Hospital "St. Ivan Rilski", Medical University of Sofia, 1431 Sofia, Bulgaria.
Medical University of Sofia · BGBulgarian Academy of Sciences · BGTokuda Hospital · BG

Funding

Bulgarian Science Fund КП-06-Н23/8-18.12.2018гBulgarian Scientific Society of Immuno-oncology (BSSI)
6 · The paper itself

Abstract

The central hypothesis for the development of glioblastoma multiforme (GBM) postulates that the tumor begins its development by transforming neural stem cells into cancer stem cells (CSC). Recently, it has become clear that another kind of stem cell, the mesenchymal stem cell (MSC), plays a role in the tumor stroma. Mesenchymal stem cells, along with their typical markers, can express neural markers and are capable of neural transdifferentiation. From this perspective, it is hypothesized that MSCs can give rise to CSC. In addition, MSCs suppress the immune cells through direct contact and secretory factors. Photodynamic therapy aims to selectively accumulate a photosensitizer in neoplastic cells, forming reactive oxygen species (ROS) upon irradiation, initiating death pathways. In our experiments, MSCs from 15 glioblastomas (GB-MSC) were isolated and cultured. The cells were treated with 5-ALA and irradiated. Flow cytometry and ELISA were used to detect the marker expression and soluble-factor secretion. The MSCs' neural markers, Nestin, Sox2, and glial fibrillary acid protein (GFAP), were down-regulated, but the expression levels of the mesenchymal markers CD73, CD90, and CD105 were retained. The GB-MSCs also reduced their expression of PD-L1 and increased their secretion of PGE2. Our results give us grounds to speculate that the photodynamic impact on GB-MSCs reduces their capacity for neural transdifferentiation.

Indexed as

5-ALAglioblastoma multiformemesenchymal stem cellsphotodynamic therapy

Identifiers

PMID36975539
PMCPMC10047864
OpenAlexW4328103575

What OpenQuestion holds

Textfull text, public
LicenceCC BY
reference markers read1
measurements read36
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.